Skip to main content

Table 6 Utility decrements

From: Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

Event

Values

Reference

Ischemic heart disease

−0.090

[29]

Myocardial infarction (non fatal)

−0.055

[29]

Congestive heart failure

−0.108

[29]

Stroke (non fatal)

−0.164

[29]

Amputation

−0.280

[29]

Renal failure

−0.379

[30]

Symptomatic hypoglycemia risk

−0.014

[32]

Severe hypoglycemia

−0.047

[32]

Weight increase (per kg)

−0.002

[31]